Moderna Sinks 18% on Leaked Melanoma Data: “Benefit Was Greater After Six Months”
Moderna's stock fell 17.6% to $202.63 after leaked Phase 3 data for its melanoma vaccine showed a 42% risk reduction, below investor expectations. The data showed a 58% risk reduction after six months. Moderna and Merck, which shares costs and profits, are awaiting full data presentation at ESMO. Analysts consider the data approvable but are reassessing commercial potential.
How this was made
The 30-second read
Why it matters
The leak of Phase 3 results before the official presentation caused a sharp sell‑off, highlighting the market's sensitivity to trial outcomes.
Market read
First disclosure of Phase 3 data leads to a 17.6% share decline, creating immediate trading opportunities.
What to watch
The partnership with Merck and potential regulatory approval pathways may mitigate the impact of the initial efficacy shortfall.
Background
Moderna's intismeran is a personalized melanoma vaccine co‑developed with Merck, with data slated for presentation at ESMO.
Ticker impact
Leaked Phase 3 data for intismeran showed lower efficacy than expected, triggering a 17.6% drop in Moderna's share price.
likely continued pressure as the market prices in weaker efficacy data
The unexpected efficacy gap and large intraday sell‑off suggest traders will stay cautious pending further data.
Market effects
Biotech sector may see broader risk aversion as trial data leaks raise concerns about data security and timing of announcements.
US biotech stocks could experience short‑term pullback, while European peers may be less affected.
Large move in a major US biotech could influence global risk sentiment in the healthcare space.
Counterpoint
If the post‑six‑month analysis holds, the vaccine could still deliver meaningful long‑term benefit, offering a buying opportunity at depressed prices.
Key entities
- companyModerna
US‑listed biotech developing the intismeran melanoma vaccine.
- companyMerck
Partner sharing costs and profits of the intismeran program.
